Study shows new obesity treatment semaglutide causes similar weight loss across different age groups
E-Mail The STEP trials published over the past year have established the efficacy and safety of semaglutide in treating patients with obesity. A new study analysing the effects of this treatment in different age groups presented at this year's European Congress on Obesity (held online, 10-13 May), shows that it has similar effectiveness across different age groups with regard to weight loss (under 40 years, 40-60 years, and 60 years and over). However when looking at percentage body fat and lean body mass changes, semaglutide was found to to have a more pronounced effect in patients aged un...